Advertisement

Topics

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

10:33 EST 14 Jan 2019 | OncLive

Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.

Original Article: Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

NEXT ARTICLE

More From BioPortfolio on "Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...